AU2018233007B2 — Proteasome inhibitors
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2020-07-23 · 6y expired
What this patent protects
H:\rbr\nterwoven\NR'ortbl\DCC\RBR\17746632_1.doc-9/21/2018 ABSTRACT The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the 5 invention and methods of using the com…
USPTO Abstract
H:\rbr\nterwoven\NR'ortbl\DCC\RBR\17746632_1.doc-9/21/2018 ABSTRACT The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the 5 invention and methods of using the compositions in the treatment of various diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.